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VaccinationIntroduction: In 2013, the Netherlands Pharmacovigilance Center Lareb published an overview of reports
of long-lasting fatigue following bivalent HPV-vaccination (2vHPV). After an update of this overview in
2015, concerns regarding the safety of 2vHPV was picked up by the media, which led to further reports
of long-lasting fatigue. Therefore, the Dutch National Institute for Public Health and the Environment
(RIVM) investigated a possible association between HPV-vaccination and long-term fatigue.
Methods: In this retrospective cohort study conducted in the Integrated Primary Care Information data-
base, we investigated the occurrence of chronic fatigue syndrome (CFS), fatigue 6 months and 3–
6 months in all girls born in 1991–2000 during the follow-up period January 1st 2007-December 31st
2014 (2007–2008 pre-vaccination and 2009–2014 post-vaccination). Patients with certain fatigue
6 mwere asked for consent to link their primary care information with vaccination data. Incidence rates
per 10,000 person years (PY) for 12–16-year-old girls were compared between pre- and post-HPV-
vaccine era. A self-controlled case series (SCCS) analysis was performed using consenting vaccinated
cases. A primary high-risk period of 12 months after each dose was defined.
Results: The cohort consisted of 69,429 12–16-year-old girls accounting for 2758 PY pre-vaccination and
57,214 PY post-vaccination. Differences between pre- and post-vaccination incidences (CFS: 3.6 (95% CI
0.5–25.7)/10,000 PY and 0.9 (0.4–2.1); certain fatigue 6 m: 7.3 (1.8–29.0) and 19.4 (16.1–23.4); certain
fatigue 3–6 m: 0.0 and 16.6 (13.6–20.3), respectively) were not statistically significant. SCCS analyses in
16 consenting vaccinated cases resulted in an age-adjusted RR of 0.62 (95%CI 0.07–5.49).
Conclusions: Fatigue 6 m and 3–6 m was frequently found among adolescent girls, but CFS was rarely
diagnosed. No statistically significant increased incidence rates were found post-vaccination compared
to similar age groups of girls pre-vaccination. The SCCS analysis included a low number of cases but
revealed no elevated risk of certain fatigue 6 m in the high-risk period.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since 2006, the bivalent HPV vaccine (2vHPV) has been licensed
for the prevention of cervical cancer. In the Netherlands, routine
2vHPV vaccination of 12-year-old girls was introduced in the
National Immunization Program (NIP) in 2010 (born from 1997onwards). In 2009, a catch-up campaign was carried out for girls
born between 1993 and 1996. Vaccination coverage of the catch-
up campaign was 52.3%. Coverage among the regular campaign
increased from 56.0% in 2010 to 61.0% in 2013/2014 but declined
again to 53.4% in 2015 [1].
Several years after the introduction of HPV-vaccination, various
publications raised concerns regarding adverse events (AE) [2–5].
From 2013 onwards, the Danish Health and Medicines Authority
received a number of reports regarding suspected postural
orthostatic tachycardia syndrome (POTS) after vaccination with
the quadrivalent vaccine (4vHPV) and informed the European
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Committee (PRAC) in September 2013. Taking into account all
available information, the PRAC concluded in November 2015 that
the evidence did not support the theory that HPV-vaccines caused
POTS [6], although this conclusion was criticized by the Nordic
Cochrane Center [7].
A frequent andmajor comorbidity of POTS is chronic fatigue syn-
drome (CFS) [8,9]. These two conditions frequently appear together
[10], and the majority of patients with POTS also fulfill the criteria
for CFS [11]. Fatigue is a well-known symptom in adolescence and
often lasts for several months. In 1997, the CFS prevalence was esti-
mated at approximately 10 per 10,000 GP patients and 1–2 per
10,000 teenagers [12–14]. In 2005, van der Linden et al. reported
that the incidence of GP consultation for fatigue (ICPC-code A04
(fatigue/weakness), independent of duration) was 10 per 1000 for
girls around the age of 10 years, and increased to a peak of 48 per
1000 for girls at the age of 15 [15]. Ter Wolbeek et al. performed
a school-based study with questionnaires among adolescents and
found that 20% of girls reported severe fatigue [16]. In 2011, Nijhof
et al. found a CFS incidence of 12 per 100,000 adolescents per year
as diagnosed by a GP or pediatrician [17].
The risk of CFS in relation to the 2vHPV and the 4vHPV vaccine
was investigated in UK and Norway, respectively. No increased risk
of fatigue syndromes for vaccinated girls was found [18–20].
In 2013, the Netherlands Pharmacovigilance Center Lareb pub-
lished an overview of the reports of long-lasting fatigue possibly
associated with 2vHPV [21]. After an update of this overview in
2015, concerns about the safety of the HPV-vaccine was picked
up by the Dutch media. In the month following this media atten-
tion, Lareb received more than one hundred reports concerning
AEs following 2vHPV. In total, Lareb received 256 reports concern-
ing long-lasting fatigue (2 months) between January 1, 2009 and
October 31, 2016, the majority of which were received after the
increased media attention in 2012 and 2015. Based on the analysis
of these reports, Lareb concluded that a causal relation between
2vHPV and long-lasting symptoms could not be confirmed nor
excluded [22]. Recent figures regarding background incidences of
fatigue and CFS in the Netherlands are not available. In addition,
no data in the Netherlands was available stratified by HPV-
vaccination status. Therefore, following the recommendation of
Lareb, the National Institute for Public Health and the Environment
(RIVM) investigated a possible association between 2vHPV and
long-term fatigue.2. Methods
2.1. Study design
A retrospective cohort study among adolescent girls was
conducted to study the possible association between HPV-
vaccination and CFS or long-term fatigue symptoms with a
duration of 6 months and 3–6 months. A cohort analysis was per-
formed on the entire study cohort, to avoid selection and to get
power. Within this cohort, cases with diagnosed CFS or certain fati-
gue 6 m were asked for informed consent to collect their HPV-
vaccination status. Data from the cases that provided consent
was analyzed using a self-controlled case series approach. In this
analysis only vaccinated cases were included; cases act as their
own controls in order to correct for time-independent
confounders.2.2. Setting
The study was conducted using the Integrated Primary Care
Information (IPCI) database (Erasmus Medical Center, the Nether-lands). The IPCI-database is a longitudinal collection of electronic
patient records from Dutch GPs into a central research database
established since 1989. At present, the database contains informa-
tion on more than 1,500,000 patients [23].
2.3. Cohort definition
The study cohort comprised all girls born between 1991 and
2000 for the study period January 1st 2007–December 31st 2014.
The calendar years 2007–2008 were classified as the pre-
vaccination era, and the years 2009–2014 were classified as post-
vaccination. The first date of follow-up was January 1st 2007, or
the date at which 1 year of valid data history in the IPCI-
database was accumulated, whatever was the latest. The end of
follow-up was December 31st 2014 or the end of registration of
the patient, death or last IPCI data delivery.
2.4. Outcome selection
Cases were identified from the electronic records if they met the
following criteria: the International Classification of Primary Care
(ICPC) code A04.01 (chronic fatigue syndrome (CFS)) or ICPC-
codes A04/A04.00 (fatigue/weakness) or ‘moe’ (Dutch for fatigue)
in the free text. This Dutch word covers all synonyms (such as
‘moeheid’ and ‘vermoeidheid’) for fatigue syndromes and thus
was considered as a robust search term. Cases who met any of
the following criteria were excluded: words containing ‘moe’ but
it had nothing to do with fatigue (e.g., moeder = mother). In addi-
tion, we excluded fatigue cases with a concomitant diagnosis other
than those that presented in the inclusion criteria on the same con-
sultation date. Thereafter, selected cases were manually validated
and coded for the onset and duration of the fatigue and concomi-
tant symptoms included in the case definition of CFS [24].
We defined different levels of evidence for long-term fatigue
symptoms:
1. ICPC-code A04.01 (CFS)
2. ICPC-code A04/A04.00 (fatigue/weakness) or ’fatigue’ in the free
text, with a duration of fatigue longer than 6 months and at
least 4 of the following symptoms [24]: malaise after exertion
lasting at least 24 h; unrefreshing sleep; significant deteriora-
tion of short-term memory or concentration; joint pain without
swelling or redness; headaches of a new type, pattern or sever-
ity; tender lymph nodes in the neck or armpit; and regularly or
frequently a sore throat.
3. ICPC-code A04/A04.00 or ’fatigue’ in the free text, with a dura-
tion of fatigue 6 months or as stated by the GP as ’chronic’ and
2–3 of the symptoms (see point 2).
4. ICPC-code A04/A04.00 or ’fatigue’ in the free text with a dura-
tion of fatigue 6 months or as stated by the GP as ’chronic’
and <2 of the symptoms (see point 2).
5. ICPC-code A04/A04.00 or ’fatigue’ in the free text with a dura-
tion of fatigue possibly 6 months (i.e., multiple fatigue con-
sults over time but unknown if the complaints continued over
time or were independent events).
6. ICPC-code A04/A04.00 or ’fatigue’ in the free text with a dura-
tion of the fatigue 3–6 months or as stated by the GP as ’long
lasting’.
7. ICPC-code A04/A04.00 or ’fatigue’ in the free text with a dura-
tion of the fatigue possibly 3–6 months (see also point 5) or
as stated by the GP as ’long lasting’.
The date of onset was obtained from the first fatigue record in
the GP-database, in case a clear date of the start of the fatigue
symptoms was indicated in the record. Because the date of onset
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record in the GP database was used as the index date for statistical
analyses. The duration of fatigue symptoms was defined as the
time of the existence of fatigue as indicated by the patient in the
first fatigue consult by the GP plus the duration of the fatigue
symptoms indicated by the follow-up consults in the GP-
database, i.e., up to the last fatigue consult.
GPs of validated cases with certain fatigue 6 m (level 1–4)
who were eligible for HPV-vaccination, i.e., girls born in 1993–
2000, received an invitation letter to contribute to the study. If
the GP was willing to participate, the selected girls from his/her
practice received an information letter and an informed consent
form through this GP. The informed consent form asked for per-
mission to link their primary care information with the HPV-
vaccination data. For girls younger than 18 years, permission of
her parents/guardians was also required.
2.5. Vaccination status
In the Netherlands, an electronic national immunization regis-
ter called ‘Præventis’ was implemented in 2005 [25]. Præventis
is primarily used for NIP-invitations and to register and validate
administered vaccinations. In addition, Præventis allows for the
production of (sub)national vaccination coverage estimates with
high accuracy and additional research, for instance, on vaccine
safety, by linking it with disease registers. The HPV-vaccination
status and dates of vaccine administration were obtained from this
registry for all girls who gave consent for linkage.
2.6. Statistical analysis
Incidence rates (IRs) of long-term fatigue among 12–16-year-
old girls were calculated for 2007–2008 (pre-vaccination) and for
2009–2013 (post vaccination) by level of evidence (see above) or
a combination of these levels:
 CFS chronic fatigue syndrome (level 1);
 CF6 certain fatigue 6 months (level 1–4);
 PF6 possible and certain fatigue 6 months (level 1–5);
 CF3 certain fatigue 3–6 months (level 6);
 PF3 possible and certain fatigue 3–6 months (level 6–7).
IRs for 2014 were not computed to correct for the need to have
a certain follow-up after the start of fatigue in order to be classified
as long-term fatigue. Incidence rate ratios (IRRs) for the post- ver-
sus pre-vaccination period were calculated and adjusted for age
using Poisson regression.
Within the CF6 cases who provided consent, were HPV-
vaccinated and had sufficient follow-up to capture high- andFig. 1. Inclusion criteria fnon-high-risk time, a self-controlled case series (SCCS) analysis
was conducted to estimate the relative incidence of CF6 following
HPV-vaccine exposure in high-risk periods compared to non-high-
risk periods (Fig. 1), adjusted for age. A primary high-risk period of
12 months following each dose was defined. In this analysis, the
last 6 months of the study period were censored in order to correct
for the need of a certain follow-up for case ascertainment. Since the
potential risk period to develop fatigue after HPV-vaccination is
not clear, sensitivity analyses were performed using two different
high-risk periods, i.e., 6 and 18 months, and one using cases only
for which a date of onset of fatigue symptoms was known.2.7. Ethical approval
This research was exempted from review by the medical ethics
committee of Erasmus Medical Center, Rotterdam, the Netherlands
(protocol number MEC-2015-629).3. Results
3.1. Incidences
The cohort consisted of 69,429 12–16-year-old girls accounting
for 2759 PY pre-vaccination and 57,214 PY post-vaccination.
IRs of CF6 were the lowest, whereas IRs of PF6 and PF3 were
much higher. Post-vaccination, IRs increased with age, peaking at
14–16 years of age and declining thereafter (Fig. 2). The age-
related IR was similar in the pre- and post-vaccination periods,
although the pre-vaccination incidence at 17 years was relatively
high (as were the confidence intervals).
IRs per 10,000 PY of CF6 for 12–16-year-old girls declined
slightly between 2007 and 2009 (13.2 (95%CI 1.9–93.6) and 5.1
(1.3–20.3), respectively) but increased slightly in 2010 to 24.3
(14.9–39.6) and stayed stable up to 2013 (Fig. 3). The IRs of PF6
increased from 2007 up to 302.5 (252.1–362.8) in 2009 and
declined thereafter to 119.8 (105.2–136.4) in 2013. IRs of PF3
remained more or less stable since 2008.
Post-vaccination IRs of CF6 for 12–16-year-old girls were
slightly higher, although not statistically significant, than in the
pre-vaccination period (IRR = 2.70 (0.67–10.9); Table 1). When
comparing IRs of PF6, post-vaccination rates were much lower
than the pre-vaccination rates (IRR = 0.76 (0.60–0.96)). For CF3, a
higher post-vaccination IR was found than for pre-vaccination,
where no cases were found. Post-vaccination IRs for PF3 were only
slightly higher than in the pre-vaccination period (IRR = 1.72
(0.76–3.87)).or the SCCS analysis.
Fig. 3. Incidences of certain and possible fatigue 6 months and 3–6 months per year for 12–16-year-old girls. PY = person years, CF6 = certain fatigue 6 months (criteria 1–
4), PF6 = possible and certain fatigue 6 months (criteria 1–5), PF3 = possible and certain fatigue 3–6 months (criteria 6–7).
Fig. 2. Age distribution of certain and possible fatigue 6 months and 3–6 months in the pre- and post-vaccination period. PY = person years, CF6 = certain fatigue 6 months
(criteria 1–4), PF6 = possible and certain fatigue 6 months (criteria 1 to 5), PF3 = possible and certain fatigue 3–6 months (criteria 6–7). *not estimated, due to restriction of
birth cohorts to 1991–2000.
Table 1
Pre- and post-vaccination period incidences of long-term fatigue for 12–16-year-old girls.










1 CFS 1 (0.03) 2758 3.6 (0.5–25.7) 5 (0.01) 57,214 0.9 (0.4–2.1) 0.24 (0.03–2.09)
1–4 CF6 2 (0.05) 2758 7.3 (1.8–29.0) 111 (0.17) 57,092 19.4 (16.1–23.4) 2.70 (0.67–10.9)
1–5 PF6 73 (1.91) 2715 268.9 (213.7–338.2) 1117 (1.74) 55,286 202.0 (190.5–214.2) 0.76 (0.60–0.96)
6 CF3 0 (0.00) 2759 0.0 95 (0.15) 57,101 16.6 (13.6–20.3) NA
6–7 PF3 6 (0.16) 2755 21.8 (9.8–48.5) 212 (0.32) 56,924 37.2 (32.6–42.6) 1.72 (0.76–3.87)
PY = person years, CI = confidence interval, CFS = chronic fatigue syndrome (criteria 1), CF6 = certain fatigue 6 months (criteria 1–4), PF6 = possible and certain fatigue
6 months (criteria 1–5), CF3 = certain fatigue 3–6 months (criteria 6), PF3 = possible and certain fatigue 3–6 months (criteria 6–7), IRR = incidence rate ratio.
* According to the criteria described in the methods.
# Adjusted for age.
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Two hundred six GPs (for 484 cases) were contacted to ask for
participation, and 52% responded positively (Table 2). Participatingand non-participating GPs were geographically distributed
throughout the country and comparable regarding practice size.
Slightly more participating GPs are male than non-participating
GPs (73% versus 66%). Consent to allow for linkage was received
Table 3
SCCS analysis with a high-risk period of 12 months after each dose and sensitivity
analysis.
Crude Adjusted for age
(12–13, 14–15,
16–17, 18–19, 20–21 yrs)
High-risk period 12 months
Within high-risk period
N events 2
N person time (days) 5469
Non-high-risk period
N events 14
N person time (days) 24,749
RR (95% CI) 0.51 (0.11–2.41) 0.62 (0.07–5.49)
High-risk period 6 months
Within high-risk period*
N events 0
N person time (days) 2937
Non-high-risk period
N events 16
N person time (days) 27,281
RR (95% CI) NA NA
High-risk period 18 months
Within high-risk period*
N events 2
N person time (days) 8104
Non-high-risk period
N events 14
N person time (days) 22,114
RR (95% CI) 0.27 (0.06–1.24) 0.17 (0.02–1.52)
Cases for which date of symptoms is known, high-risk period 12 months
Within high-risk period*
N events 2
N person time (days) 5469
Non-high-risk period
N events 11
N person time (days) 24,749
RR (95% CI) 0.29 (0.03–2.52)
Table 2
Participation for data linkage between primary care data
and vaccination data (A) and age distribution of cases
included in the SCCS analysis (B).
A. Participation N
GPs who received an invitation letter 206
Consent GPs 107




Follow-up time within the high-risk period 16
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(Table 2). Of them, 16 vaccinated cases had a follow-up time in
the high- and non-high-risk periods and therefore could be
included in the SCCS analysis (Table 2). Five of them were vacci-
nated in the catch-up campaign (birth cohort 1993–1996) and 11
through the regular NIP (birth cohort 1997–2000).
One case had a fatigue diagnosis before she received the first
vaccine dose, and for the other 15 cases the median time between
the most recent vaccine dose and the date of first fatigue recorded
in the GP database was 765 days (range 191–1872 days). A lower
risk of fatigue was found in the high-risk period versus the non-
high-risk period (adjusted RR 0.62, 95%CI 0.07–5.49; Table 3). This
lower risk was sustained in the sensitivity analysis with different
high-risk periods and analysis of only cases with a known date of
onset of the fatigue symptoms (Table 3).
4. Discussion
This cohort and SCCS analysis showed no significant increased
association between long-term fatigue and bivalent HPV-
vaccination. Fatigue 6 m and 3–6 m occurred frequently among
adolescent girls, but CFS was rarely diagnosed by the GP. The
cohort analysis had the most power and no selection and consis-
tently showed that the IRs of CFS, fatigue 6 m (CF6 and PF6)
and 3–6 m (CF3 and PF3) were not statistically significantly ele-
vated in the post-vaccination period compared to the pre-
vaccination period. There was no indication that the age pattern,
peaking at age 14–16 years of age, have changed between the
pre- and post-vaccination period, although a somewhat higher
incidence at 17 years of age in the pre-vaccination period. The SCCS
analysis, where HPV-vaccination status was linked on a personal
level, did not show an increased risk of certain fatigue 6 m
(CF6) within 12 months after HPV doses, but because of the low
response for consent of data linkage, this analysis had little power.
Several case reports have been published that described symp-
toms of POTS and/or CFS in relation to 4vHPV [3,26,27]. However,
two observational studies found no association [19,20]. In the UK,
an SCCS approach was applied among 187 vaccinated girls with
CFS to estimate their risk in the 12 months after HPV-
vaccination. No association was found between vaccination with
2vHPV and CFS [19]. Similarly, in Norway, no indication of an
increased risk of CFS/ME (myalgic encephalomyelitis) following
HPV-vaccination was observed among girls in the first six birth
cohorts offered 4vHPV through the NIP [20]. Although study
designs differ, our results are in accordance with the results in
the UK and Norway. Thus, the signals raised by several case reports
were not confirmed in observational studies. In addition, three
reviews also did not detect any unusual reporting of POTS afterHPV-vaccination that would suggest a safety problem [28–30].
Overall, the Global Advisory Committee on Vaccine Safety (GACVS)
concluded that there is still no evidence to suggest a causal associ-
ation between HPV-vaccine and POTS or other diverse symptoms
[31].
In the present study, we found slightly higher but not statisti-
cally significant post-vaccination IRs of CF6 and CF3 than in the
pre-vaccination period (CF6: 19.4 vs. 7.3, IRR = 2.70 (0.67–10.9);
CF3: 16.6 vs. 0.0). When we compared incidences of fatigue 6 m
and 3–6 m including possible cases (PF6 and PF3), the pre- and
post-vaccination incidences were comparable. The number of CF6
and CF3 were very low, especially in the pre-vaccination period
(2 and 0, respectively per 2758 PY, vs. 111 and 95 per 57,214 PY
in the post-vaccination period), since there was only limited
follow-up time in the pre-vaccination period. Media attention on
safety concerns about HPV-vaccination, which have been raised
frequently in the Netherlands (i.e. especially in 2009, March
2012, November 2013, March 2015 and November 2016), often
on chronic fatigue symptoms, could have increased awareness
about this syndrome. This might possibly have led to more GP con-
sultations in those periods leading to a higher estimate of the inci-
dence compared to periods with no media attention. This could
explain the relatively high incidence of fatigue PF6 in 2009. How-
ever, no increased incidence of PF6 was seen in 2012 and 2013.
Of the patients included in the SCCS analysis, one was diagnosed
within 3 months after such increased media attention, however
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were diagnosed at least 6 months following increased media atten-
tion. Therefore, we think that the impact of this media attention
was low in this analysis.
Classification of cases using routine health care records was dif-
ficult. For several girls, there were several fatigue consults over
time. However, in most cases, it was unknown if the complaints
persisted over time or whether these were independent events.
These cases were defined as possible cases. Therefore, we assumed
that the incidence of certain cases is an underestimation and the
incidence of possible cases an overestimation of the true incidence.
This assumption seems to be confirmed when the incidences found
in our study were compared with other Dutch estimations of GP
consultations for fatigue and CFS among adolescents [15,17]. Inci-
dences of possible and certain fatigue 6 m (7.3–268.9 per 10,000
PY) were, despite a wide range, in line with incidences of GP con-
sultations for fatigue (ICPC-code A04, independent of duration)
found by Van der Linden et al. in 2005 (one-year incidence
20.1/1000 girls <18 years) [15]. Post-vaccination CFS incidences
were comparable with the CFS incidence found in the pre-
vaccination period by Nijhof et al. using GP-data from 2008
(12/100,000 adolescents per year) [17]. Our study also showed that
the incidence of fatigue6 m and 3–6 m increased with year of age
to peak at 14–16 years and declined again thereafter. This same
pattern with a peak at 15 years of age was seen among girls in
studies conducted before the introduction of HPV-vaccination in
the Netherlands, such as by M. ter Wolbeek et al. among approxi-
mately 3400 high school students in 2002–2005 (personal commu-
nication), by S. Nijhof et al. among 135 adolescent CFS patients in
2008–2010 [32] and Van der Linden et al. GP consultations for fati-
gue in 2005 [15]. However, in our study, the pre-vaccination inci-
dence at 17 years of age was relatively high. This finding might be
explained by the low amount of person time and cases in the pre-
vaccination period, which resulted in estimations with a wide con-
fidence interval.
Overall, the incidence of fatigue is relatively high in adolescents,
particularly among girls [16]. Life-style characteristics such as
sleep and physical activity, and depression, anxiety and chronic
fatigue-related symptoms are associated with the onset and persis-
tence of fatigue [16,33]. In girls, early menarche and medication
use also play a role [16]. In contrast, CFS is a relatively rare but dis-
abling disorder, which often results in considerable absence from
school leading to long-term consequences for the patients’ educa-
tional and social development [17].
A comprehensive description of CFS is the bio-psycho-social
approach, which distinguishes between predisposing, precipitating
and perpetuating factors at both the biological (such as genetic or
physical vulnerability, trauma or physical stress and disturbed
sleep-wake cycles or disordered food intake) and the psychosocial
level (such as anxiety, depression, personality disorders, somatiza-
tion, stress and physiological trauma) [34]. Changes in social influ-
ences, such as somatization of the parents, a family member with
physical or mental diseases, life events, isolation or excessive med-
ication consumption, might also be a cause of the increasing inci-
dence of long-term fatigue symptoms and/or an increase in
healthcare use due to long-term fatigue symptoms [34].
In a nationwide hospital register-based study in Norway, it was
found that between 2009 and 2014 the incidence rate of CFS
increased annually [20]. However, a similar increase was found
among girls as well as among boys despite only girls being vacci-
nated with the 4vHPV vaccine [20]. In contrast, in the UK no
change in CFS incidence was observed among girls in the three
years following the introduction of 2vHPV [19]. Conversely, a
decreasing trend in fatigue syndromes was observed for boys. This
trend was probably natural random variation, as no other explana-
tion was found [19].One of the strengths of this study was the ability to include fati-
gue cases from a large time period, which included two years
before and six years after introduction of HPV-vaccination. A large
longitudinal database of more than 600 GPs, representative for the
Netherlands, including more than 1.5 million inhabitants was used
[23]. Another advantage of this GP-database was the availability of
free text fields from the GPs. This free text was used to indicate
fatigue symptoms and the duration of the fatigue but also to put
the fatigue symptoms in context to other complaints or diseases.
To use the full potential of this free text, all automatically selected
cases were validated and coded manually.
The relationship between HPV-vaccination and fatigue 6 m
was assessed in two ways: first, an ecological method, comparing
population-based incidence rates before and after introduction of
HPV-vaccination, and second, by using SCCS analysis. This method
was chosen, as it uses only cases, and it controls for confounders
that do not vary over time. In addition, the method was most effi-
cient, given that consent was required to be able to link the vacci-
nation status.
Despite its strength, this study also has several limitations,
given its observational nature. Misclassification of the outcome
may easily occur since the diagnosis of CFS is complex. According
to the case definition, additional symptoms to meet the diagnoses
and exclusion of other illnesses that could cause similar complaints
are required [24]. For this reason, we defined a level of evidence for
CFS depending on the duration of fatigue symptoms and the pres-
ence of additional symptoms as stated in the case definition.
Unfortunately, the presence of these symptoms was largely
unknown, as they were rarely reported in the medical records.
CFS is also a rule out diagnosis; in order to be classified as CFS,
no other somatic or psychiatric cause for fatigue should be present.
We therefore excluded all cases with concomitant diseases on the
same consultation date. This approach possibly has resulted in an
underestimation of incidences as cases with a concomitant disease
that could not explain the fatigue were also excluded. In addition, if
CFS was diagnosed by a specialist, not all GPs might have coded
this as such in their system and therefore could have been missed.
For this reason we chose to select all fatigue diagnoses and thereby
prevented that this kind of cases were missed.
Moreover, the date of onset of fatigue symptoms was largely
unknown or unclear. We therefore used the date of first fatigue
consult as an index date. However, some patients go to their GP
within several days after onset of symptoms, while other patients
wait for up to several years before going to their GP. Therefore, we
performed sensitivity analyses of the cases for which a first date of
onset of fatigue symptoms was known, and these analyses did not
change the conclusion.
Selection issues may have been a problem in the SCCS analysis.
Due to privacy concerns, GP records and vaccination records could
not be linked probabilistically in a de-identified manner similar to
what we had tested successfully before [35]; instead, we had to
approach cases for consent to link their GP data with the vaccina-
tion registry data. Within the IPCI database, approaching patients
can only be done through their participating GP, who holds the
key to identity. Unfortunately, the multiple steps to ask during
the consent process resulted in a low participation rate of both
GPs (52% of invited GPs) and cases (20% of invited patients). Partic-
ipating cases were much more likely to be vaccinated than the reg-
ular vaccination rate, suggesting potential selection bias.
Additionally, the distribution in the date of the first fatigue consult
and onset of symptoms did not differ for cases who gave consent
compared to those who did not, so we have no indication for
response bias in our study. Since the SCCS was only restricted to
vaccinated cases, and the estimate was low, we believe that this
bias may not have affected our conclusion. Nevertheless, if selec-
tion bias is still included this may have led to an overestimation
6802 T.M. Schurink-van’t Klooster et al. / Vaccine 36 (2018) 6796–6802of the relative risk. Given the loss of information and power and
the potential for bias when consent is required, we recommend
that other strategies for linkage be investigated in the Netherlands
if public health is potentially at stake.
5. Conclusions
In this study, no statistically significantly increased post-
vaccination incidence rates of CFS, fatigue 6 m or 3–6 m were
found compared to the pre-vaccination incidence rates for girls
of the same age groups. However, fatigue 6 m and 3–6 m were
frequently found, but CFS was rarely diagnosed, and its incidence
rates were in line with the results of previous studies. Following
linkage of primary care information with the vaccination registry,
no elevated risk of certain fatigue 6 m in the high-risk period of
12 months after each HPV-dose was revealed. We did not find evi-
dence for an increased risk of fatigue syndromes following HPV-
vaccination, although the sample size of the present study was
small. This may result in a lack of power to detect small
differences.
Meetings
These results were presented at the 36th Annual Meeting of the
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